Nanjing Ruikewei Biomedical Co. Ltd.

2022年医保目录中的协议期内谈判药品，西药涵盖消化道和代谢方面药物、血液和造血器官药、心血管系统用药、β-受体阻滞剂、调节血脂药、皮肤病用药、泌尿生殖系统药和性激素、除性激素和胰岛素外的全身激素制剂、全身用抗感染药、抗肿瘤药及免疫调节剂、肌肉骨骼系统药物、神经系统药物、呼吸系统药物、感觉器官药物、其他类共16种；中药涵盖内科用药、肿瘤用药、骨伤科用药、妇科用药、民族药共5个类别。2022年医保目录将从2023年3月1日起实施，本文将分析协议期内的心血管系统用药。数据来自于PDB药物综合数据库（pdb.pharmadl.com），CPM新药研发监测数据库（cpm.pharmadl.com）。心脏治疗药1.注射用重组人脑利钠肽：该药医保支付标准为445元（0.5mg/支），限二级及以上医疗机构用于规范治疗效果不佳的急性失代偿性心力衰竭短期治疗，由成都诺迪康生物制药有限公司申报上市（2005.4.11）。该药与内源脑利钠肽具有相同的氨基酸序列、空间结构、生物活性，人体在补充几倍甚至十几倍的外源性脑利钠肽后，能迅速有效治疗心力衰竭，改善预后。自2012年以来，该药销售额逐年攀升，2022年达到了峰值7.74亿元。图1：注射用重组人脑利钠肽销售情况2.丹参酮ⅡA磺酸钠注射液：该药医保支付标准为11.9元（2ml：10mg/支），由上海上药第一生化药业有限公司申报上市（2003.9.27）。该药适用于缺血性心脑血管疾病、脑血栓形成、末梢循环障碍疾病以及高血压等疾病的辅助治疗，自2012年起，该药销售额稳定在2.5亿元上下，2020年下滑至1.34亿元，2022年仅为0.73亿元。图2：丹参酮ⅡA磺酸钠注射液销售情况3.瑞加诺生注射液：该药医保支付标准保密，可以作为放射性核素心肌灌注显像（MPI）中使用的一种负荷药物，与一般的腺苷注射液相比，在有效性、安全性等方面具有优势，由南京瑞克卫生物医药有限公司完成首仿（2021.10.26），2022年销售额为41万元。销售额排名前五的省份是湖北省（27.35%）、辽宁省（23.93%）、江苏省（14.34%）、上海市（12.77%）、河北省（9.77%）。图3：瑞加诺生注射液销售情况4.非奈利酮片：该药医保支付标准保密，限2型糖尿病相关的慢性肾脏病成人患者，由Bayer AG引入国内（2022.6.28）。作为非甾体选择性盐皮质激素受体拮抗剂，该药可持续降低eGFR，并减少终末期肾病的风险，2022年销售额为4万元。图4：非奈利酮片销售情况5.波生坦片：该药医保支付标准保密，限WHO功能分级Ⅱ-Ⅳ级的肺动脉高压患者，该药最早由瑞士爱泰隆引入国内（2006.3.23）。波生坦分散片：该药医保支付标准保密，限3-12岁特发性或先天性肺动脉高压患者，该药由Janssen-Cilag AG引入国内（2019.9.5）。作为一种内皮素受体拮抗剂，可以抑制血管收缩，增加血液流量，增强心肺功能，这也是首个肺动脉高压口服治疗药物。从销售金额上看，波生坦片近几年的销售额稳定在1000万元左右，而波生坦分散片作为新品，销售额正逐年上升，2022年销售额约为300万元。图5：波生坦片/波生坦分散片销售情况6.利奥西呱片：该药医保支付标准保密，限定支付范围为术后持续性或复发性慢性血栓栓塞性肺动脉高压或不能手术的患者（WHO FC为Ⅱ-Ⅲ级）；动脉性肺动脉高压且WHO FC为Ⅱ-Ⅲ级患者的二线用药，由Bayer AG引入国内（2018.9.17）。作为一种可溶性鸟苷酸环化酶激活剂，该药可显著提高患者的运动耐量、血液动力学参数和心功能，2022年销售额为1600万元。图6：利奥西呱片销售情况7.马昔腾坦片：该药医保支付标准保密，限WHO功能分级Ⅱ-Ⅲ级的肺动脉高压患者，最早由Actelion Pharmaceuticals Ltd引入国内（2017.9.29）。该药具有组织靶向性，对ET-A受体和ET-B受体具有双重抑制作用，与波生坦相比，该药药物相互作用少、安全性良好，2022年销售额已达到6008万元。图7：马昔腾坦片销售情况年度发布2023年《全球药研新动态》《中国医院市场用药格局》（2023版）2023年《数图药讯》权威发布2021年度中国医药工业百强榜单解读中国仿制药发展报告（2022版）医药行业专项报告中国医药中间体和原料药行业调研报告中国非甾体抗炎类原料药市场调研报告中国祛痰类原料药市场调研报告中国钙拮抗剂类原料药市场调研报告中国血管紧张素Ⅱ受体拮抗剂类原料药市场调研报告中国口服血糖调节类原料药市场调研报告中国中枢兴奋类原料药市场调研报告中国抗痛风类原料药市场调研报告中国脑血管病类原料药市场调研报告END如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

每周药品注册受理数据，分门别类呈现，一目了然。（12.12-12.18）新药上市申请无。新药临床申请药品名称企业名称分类受理号APG-115胶囊苏州亚盛药业有限公司1CXHL22006761CXHL2200677APG-2575片1CXHL22006781CXHL2200679BRG01注射液广州百吉生物制药有限公司1CXSL2200487C-13-60细胞制剂重庆精准生物技术有限公司1CXSL2200478GR1802注射液重庆智翔金泰生物制药股份有限公司1CXSL2200460KP104注射液科越医药(苏州)有限公司1CXSL2200437LNK01002胶囊凌科药业(杭州)有限公司1CXHL22006901CXHL2200691UB-221 皮下注射剂联生药(扬州)生物医药有限公司1CXSL2200466WS016干混悬剂中美华世通生物医药科技(武汉)股份有限公司1CXHL2200645靶向 CD19 非病毒 PD1 定点整合 CAR-T 细胞注射液上海邦耀生物科技有限公司1CXSL2200465人脐带间充质干细胞注射液浙江泉生生物科技有限公司1CXSL2200457瑞加诺生注射液南京瑞克卫生物医药有限公司2.4CXHL2200673伊匹乌肽滴眼液深圳益信康生物科技有限公司1CXHL2200733优替德隆胶囊成都华昊中天药业有限公司2.2CXHL22006862.2CXHL2200687重组B群脑膜炎球菌疫苗(大肠杆菌)北京智飞绿竹生物制药有限公司2.6CXSL2200495注射用AP026安源医药科技(上海)有限公司1CXSL2200489注射用多西他赛(白蛋白结合型)四川科伦药物研究院有限公司2.2CXHL2200716仿制药申请药品名称企业名称分类受理号氟比洛芬凝胶贴膏湖南九典制药股份有限公司4CYHL2200076富马酸卢帕他定口服液江苏艾立康医药科技有限公司3CYHL2200078注射用奥氮平齐鲁制药有限公司3CYHL2200080进口申请药品名称企业名称分类受理号DS-1062a阿斯利康投资(中国)有限公司1JXSL2200166LY3819469注射液礼来苏州制药有限公司1JXHL2200285司柏索利单抗注射液勃林格殷格翰(中国)投资有限公司1JXSS2101030中药相关申请药品名称企业名称分类受理号芪参益气滴丸天士力医药集团股份有限公司2.3CXZL2200042注：灰色字体部分结论为不批准；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

CHICAGO, Nov. 23, 2022 /PRNewswire/ -- Veltex Corporation (OTCQB:VLXC) ("Veltex"), a Health and Wellness Acquisition Firm, is pleased to announce its wholly owned subsidiary Veltex Medical, Inc. d/b/a Veltex Recovery Group ("VRG"), in partnership with Elena Behavioral Health Services, Inc., a West Virginia Corporation, has been approved by the West Virginia Office of Health Facility Licensure and Certification, The Bureau of Medical Services ("BMS"), and The United States Drug Enforcement Agency ("DEA") to provide residential treatment for twenty-eight (28) licensed beds at its Behavioral Health Recovery center at 101 Martin Drive, Mount Hope, WV 25880 ("The Mount Hope Campus") starting November 28, 2022. Veltex seeks to develop and acquire companies which have established or advanced the latest modalities in the areas of health wellness, and recovery, specifically targeting substance use disorder ("SUD") treatment in the State of West Virginia. VRG currently operates an out-patient only SUD treatment facility at the Mount Hope Campus. The in-patient program will exclusively treat women and is a major necessity for the region to aid in the treatment of substance use disorder. Providing healing to those in need Veltex Recovery Group Announces Launch of In-Patient Services at Mount Hope Tweet this VRG has been credentialed by the Bureau of Medical Services for in-patient residential treatment with Medicaid and HMO providers Unicare, Aetna Better Health of WV; and The Health Plan ("THP"). VRG is obtaining credentialling with additional insurance carriers as well. VRG's OHFLAC Certificate of Occupancy provides for the following levels of care pursuant to the BMS provider manual Chapter 504 - Substance Use Disorder: 504.18.4 Residential Adult Services ASAM® Level 3.7 – six (6) beds; 504.18.3 Residential Adult Services ASAM® Level 3.5 – fourteen (14) beds; and 504.18.1 Residential Adult Services ASAM® Level 3.1 – eight (8) beds, full details regarding VRG's approved levels of care can be found at dhhr.wv.gov. Out-patient services at the Mount Hope Campus are now offered five (5) days per week, and VRG has established a consistent market to expand in this regard. Initially, in patient revenue is projected at $425 a day, per resident, for the first seven (7) days. Residents can then maintain this status based on the recommendations of Medical Staff and renewed prior authorizations. This program can be renewed up to a period of eighteen (18) months per resident and graduated residents open a new space for treatment of additional residents. Furthermore, VRG will gain additional revenue from services such as counseling, peer recovery services, lab work, and testing, among others. VRG leases a laboratory space within the Mount Hope Campus, to Appalachian Labs of WV, LLC and maintains lab-work collection with Charleston Area Medical Center ("CAMC") Lab Works. VRG's ultimate vision at the Mount Hope Campus will be realized in three (3) phases. Phase I, described above, will begin with a limited number of residents and will quickly escalate to twenty-eight (28) residents. Phase II, of which construction has already begun, will consist of an additional fifty (50) residents in twenty-five (25) double occupancy rooms. Phase II should be completed by early spring of 2023. Phase III will begin shortly after Phase II residents are admitted with plans to bring an additional thirty (30) residents to the Mount Hope Campus. VRG has also been approved for review by the West Virginia Alliance of Recovery Residences ("WVARR"). The WVARR certification process is designed for recovery residence program operators who are currently operating recovery housing programs in WV. All residences and levels of housing in an organization will be reviewed prior to on-site visits, including policies and procedures for homes that aren't open yet. To become a WVARR certified residence, a dwelling will need to be in operation for at least 60 days and have 60% occupancy at the time of final review. Additionally, VRG has partnered with WIN West Virginia Foundation, Inc. (Women and Infant Narcotic Rehabilitation Program). WIN is an organization self-described as women winning against Substance Use Disorder and SUD in pregnancy. The program delivers judgment free, comprehensive medical care with hope and compassion. WIN will be providing peer recovery services at the Mount Hope Campus through its four-part plan focused on prevention, treatment, peer and community support, and empowerment. VRG envisions a future where it will collaborate with West Virginia's Department of Child Protective Services to reunite mothers with children they have lost due to substance use disorder. Dr. Harry L. Haroutunian M.D., Chief Medical Director of Veltex Corporation commented, "This is a crucial step for Veltex Recovery Group and the clearing of a major hurdle for West Virginian women, the community, the Appalachian Region, and the Nation as a whole. This facility will not only give hope, but also serve as a beacon for healing in the State of West Virginia. When we help women and mothers, we help children, when we help children, we help families, when we help families, we help the community, and when we help the community, we help the world." Stephen G. Macklem, Chief Financial Officer, stated, "The barrier of entry into this industry is extreme and for good reason. Veltex Medical, Inc., our wholly owned subsidiary, required numerous licenses and inspections by both federal and state authority. Phase I is now underway at the Mount Hope Campus. Revenue generated from this phase will assist in the expansion of Phase II, along with Grants from the State of West Virginia. From a financial perspective the holding company couldn't be more pleased. We are exactly on target with the goals that have been laid out previously. Veltex Corporation's wholly owned subsidiary, Veltex Properties, Inc., a Delaware Corporation, leases the 35,000 sq.ft. facility and approximately five (5) acres of land to Veltex Corporation's wholly owned subsidiary, Veltex Medical, Inc., a Delaware Corporation. This facility and land operates as a Veltex Recovery Group Campus. Future plans in Phase IV, call for architectural drawings, permits and construction of, at least two (2), additional residential facilities on the premises to operate expanded in-patient Behavioral Health Center services. This future expansion will allow the campus to house as many as five-hundred (500) additional residents. About Veltex Corporation Veltex Corporation, (OTCQB: VLXC), incorporated in Utah September 17, 1987, is a public holding corporation, which maintains its corporate headquarters in Chicago, Illinois. Veltex's common shares trade OTC Markets under the symbol VLXC. Veltex is a premier Health and Wellness Acquisition Firm, specifically targeting Substance Use Disorder ("SUD") treatment entities. Veltex Medical, Inc. d/b/a Veltex Recovery Group ("VRG"), a Delaware corporation and Veltex Properties, Inc. ("VPI"), a Delaware corporation are both wholly owned subsidiaries of Veltex. VMI operates an approximately 30,000 Sq. Ft. out-patient substance use disorder treatment facility at 101 Martin Drive, Mount Hope, WV 25880, providing both out-patient and in-patient SUD treatments. For additional information, please visit our corporate website at: Veltex.com, and our VRG website: Veltexrecoverygroup.com Safe Harbor Statement Forward Looking Statement Safe Harbor Statement; Certain of the above statements contained in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those indicated in the forward-looking statements as a result of various factors. This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as Veltex or its management "believes," "expects," "anticipates," "foresees," "seeks," "forecasts," "estimates" "projected" or other words or phrases of similar import. Similarly, statements herein that describe Veltex's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Any statements made in this press release which are not historical facts contain certain forward-looking statements; as such term is defined in the Private Security Litigation Reform Act of 1995, concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. The actual results of the specific items described in this release, and the company's operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company, Veltex, as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company's dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update information contained in any forward-looking statement. This press release shall not be deemed a general solicitation. SOURCE Veltex Corporation